A Phase 2 interventional study of Ranibizumab 0.5mg and THR-317 8mg in Diabetes Mellitus, Diabetic Retinopathy and Macular Edema, sponsored by Oxurion. Completed at 37 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-02.
Sponsored by Oxurion · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Diabetic Retinopathy with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Diabetic Retinopathy · France.
Among the 30 studies in Diabetic Retinopathy with a site in France, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 2, and was the 17th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →5 of the 30 studies in Diabetic Retinopathy with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18+
Evolucare Technologies · Sites in France
Ages 18+
CHU de Reims · Sites in France
Ages 18+
CHU de Reims · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 4
First in 2004; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 135 across the 19 interventional studies, 101 across the 11 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 30 have an industry lead sponsor. The 10 most frequent:
Oxurion is the lead sponsor of 3 studies on the registry; none are open to participants now.
Oxurion has 8 studies filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetic Retinopathy with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06782997CHU de ReimsPerformance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy. | 2026-12-17 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Diabetic Retinopathy with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST), in subjects with central-involved diabetic macular oedema (CI-DME).
783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
This study's enrollment of 70 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Browse Diabetic Retinopathy studies →Oxurion is the lead sponsor of 3 studies on the registry; none are open to participants now.
Compared within Diabetic Retinopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive intravitreal ranibizumab in combination with THR-317
Drug: Ranibizumab 0.5mg · Drug: THR-317 8mg
Subjects will receive a sham injection in combination with intravitreal ranibizumab
Drug: Ranibizumab 0.5mg · Drug: Sham injection
3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
Also known as: Lucentis®
3 intravitreal injections of THR-317 8mg, approximately 1 month apart
3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
Change from baseline in BCVA
Time frame: At Day 84 (Month 3)
Incidence of systemic and ocular adverse events including serious adverse events
Time frame: From Day 0 to Day 140
Change from baseline in BCVA, by study visit
Time frame: From Day 0 to Day 140
Change from baseline in CST, based on spectral domain optical coherence tomography (SD-OCT), as assessed by the central reading centre, by study visit
Time frame: From Screening to Day 140
Withdrawal from repeat study treatment and reason for withdrawal
Number of subjects meeting withdrawal criteria from repeat study treatment
Time frame: At Day 28 and at Day 56
Ran from Apr 2018 to primary completion in Jul 2019, 14 months.
Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 14 months is below that.
Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TB-403